PDCD1 and neoplasm: Treatment with PD-1 ICB alone caused significant tumor growth delay, increasing median survival from 33 days (untreated) to 40 days (p = 0.0041); the addition of a single cycle of [225Ac]Ac-FAPI-46 to ICB did not further improve outcome (p = 0.2864 versus PD-1 ICB) (Fig. 4B, F,G).